Browse by author
Lookup NU author(s): Professor Hermann Josef Vormoor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Human Epstein-Barr virus-specific T cells were genetically modified to express chimeric receptors specific for human CD19, which is expressed on the cell surface of most B cell malignancies. The receptor-modified EBV-specific T cells can be expanded and maintained long term in the presence of EBV-infected B cells. They recognize autologous EBV-infected targets through their conventional T cell receptor, and allogeneic EBV-infected targets and tumor targets through their chimeric receptor. They efficiently lyse both EBV and CD19-positive tumor targets in the absence of background cytotoxicity against CD19-negative targets. Donor-derived EBV-specific T cells expressing chimeric anti-tumor receptors may represent a source of effector cells that could be safely administered to leukemia patients to eradicate minimal residual disease after allogeneic bone marrow transplantation.
Author(s): Roessig C, Scherer SP, Baer A, Vormoor J, Rooney CM, Brenner MK, Juergens H
Publication type: Article
Publication status: Published
Journal: Annals of Hematology
Issue: Suppl. 2
Print publication date: 01/09/2002
ISSN (print): 0939-5555
ISSN (electronic): 1432-0584
Notes: Conference: Third International Symposium TRANSPLANTATION IN HEMATOLOGY AND ONCOLOGY, Stem cells potential, cellular therapy, clinical perspectives. September 6 and 7, 2002, Münster, Germany.